Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma and biotech.
|Articles|January 1, 2011
- Pharmaceutical Executive-01-01-2011
- Volume 0
- Issue 0
The List: 2011
Author(s)Walter Armstrong
It's a new year. Even pharma, with its glacial timelines, has its "Out with the old, in with the new" moment. Welcome to 2011!
Advertisement
It's a new year. Even pharma, with its glacial timelines, has its "Out with the old, in with the new" moment. Welcome 2011!
Getty Images / Anna Williams
Articles in this issue
almost 16 years ago
Malta: A healthy location for the pharmaceutical industryalmost 16 years ago
Politics & PDUFAalmost 16 years ago
The Right Mix for 2011almost 16 years ago
The Night Stalkersalmost 16 years ago
Malta: A Healthy Location for the Pharma IndustryAdvertisement
Related to this article
CSL partners with Alentis Therapeutics to co-develop lixudebart, while Jiangsu Nhwa licenses a clinical-stage sleep disorder candidate to Somnivera.
Foghorn Therapeutics and Eli Lilly are discontinuing their SMARCA2 degrader Fhd-909 after Phase I data fell short on efficacy.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing
2
FDA Approves Tecentriq for Stage III dMMR Colon Cancer
3
The Most Important Lessons Learned from Building CGT Supply Chains: LogiPharma 2026
4
Viatris Acquires Pacira BioSciences for $1.65 Billion
5